Invention Grant
- Patent Title: Modulation of UBE3A-ATS expression
-
Application No.: US14409348Application Date: 2013-06-25
-
Publication No.: US09617539B2Publication Date: 2017-04-11
- Inventor: Frank Rigo , Amanda Ward , Linyan Meng , Arthur L. Beaudet
- Applicant: Ionis Pharmaceuticals, Inc. , Baylor College of Medicine
- Applicant Address: US CA Carlsbad US TX Houston
- Assignee: Ionis Pharmaceuticals, Inc.,Baylor College of Medicine
- Current Assignee: Ionis Pharmaceuticals, Inc.,Baylor College of Medicine
- Current Assignee Address: US CA Carlsbad US TX Houston
- Agency: Ionis Pharmaceuticals, Inc. Patent Dept.
- International Application: PCT/US2013/047701 WO 20130625
- International Announcement: WO2014/004572 WO 20140103
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/113 ; C07H21/04
Abstract:
Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
Public/Granted literature
- US20150191723A1 MODULATION OF UBE3A-ATS EXPRESSION Public/Granted day:2015-07-09
Information query
IPC分类:
